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Abstract
Background: Adult patients on prolonged acute mechanical ventilation (PAMV) comprise 1/3 of
all adult MV patients, consume 2/3 of hospital resources allocated to MV population, and are nearly
twice as likely to require a discharge to a skilled nursing facility (SNF). Their numbers are projected
to double by year 2020. To aid in planning for this growth, we projected their annualized days and
costs of hospital use and SNF discharges in year 2020 in the US.
Methods: We constructed a model estimating the relevant components of hospital utilization. We
computed the total days and costs for each component; we also applied the risk for SNF discharge
to the total 2020 PAMV population. The underlying assumption was that process of care does not
change over the time horizon. We performed Monte Carlo simulations to establish 95% confidence
intervals (CI) for the point estimates.
Results: Given 2020 projected PAMV volume of 605,898 cases, they will require 3.6 (95% CI 2.7–
4.8) million MV, 5.5 (95% CI 4.3–7.0) million ICU and 10.3 (95% CI 8.1–13.0) million hospital days,
representing an absolute increase of 2.1 million MV, 3.2 million ICU and 6.5 million hospital days
over year 2000, at a total inflation-adjusted cost of over $64 billion. Expected discharges to SNF
are 218,123 (95% CI 177,268–266,739), compared to 90,928 in 2000.
Conclusion: Our model suggest that the projected growth in the US in PAMV population by 2020
will result in annualized increases of more than 2, 3, and 6 million MV, ICU and hospital days,
respectively, over year 2000. Such growth requires careful planning efforts and attention to
efficiency of healthcare delivery.
Background
Healthcare institutions today are frequently faced with
stretching limited resources. In the US, factors contribut-
ing to this are significant and worsening personnel short-
ages [1-10], reductions in reimbursement [11], and in
numbers of hospital and intensive care unit (ICU) beds
[12] in the face of growing demand for healthcare [13-15].
After a decade of declines in hospital admissions, since the
mid-1990s there has been an annualized 1.5% growth in
hospital volume [16]. Similarly, total inpatient days have
stabilized over the last 10 years at about 197 million [16].
These events have occurred against the backdrop of hospi-
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tal and bed closures, resulting in a drop in hospital beds
between 1995 and 2005 from 3.3 to 2.7 per 1,000 popu-
lation [17]. Currently, nearly half of Emergency Depart-
ments (EDs) are reporting operating at or over capacity,
and one-third report some time on diversion, the most
frequent reason being the lack of staffed critical care beds
[16]. This is not surprising, since the number of ICU beds
has remained essentially unchanged between 1991 and
2004 [18].
We recently described a novel sub-population of patients
on mechanical ventilation (MV), those requiring pro-
longed acute mechanical ventilation (PAMV, defined as
MV for ≥ 96 hours), who, though comprising 1/3 of all
patients on MV, utilize 2/3 of the associated hospital
resources. [19]. Numbering about 300,000 cases in 2003,
and accounting for nearly 7 million hospital days and $16
billion in hospital costs annually [19], the PAMV volume
is projected to more than double by year 2020 [20]. This
growth, on the par with that among patients with sepsis
and severe sepsis [21-23], is far greater than previously
predicted and well outpaces the increase seen in hospital
discharges overall [3,4,16]. In the absence of information
projecting healthcare utilization for such resource-inten-
sive groups of patients, the limited hospital resources can-
not be expected to keep pace.
In the current study, we have quantified the expected US-
specific hospital bed resources and associated costs of pro-
viding care to the adult PAMV patients in year 2020. Spe-
cifically, we have calculated bed day numbers and costs
within the relevant care strata, including MV, ICU, and
hospital days that these patients may occupy. Addition-
ally, since PAMV patients are roughly 50% more likely to
be discharged to a skilled nursing facility (SNF) than those
requiring shorter term MV [19], we have projected the
numbers that will likely require such subacute care fol-
lowing their acute hospitalization.
Methods
No human subjects were enrolled in the study, and, thus,
the study was exempt from regulations guiding protection
of human subjects. We developed a model utilizing pub-
licly available inputs, and tested the robustness of the out-
come estimates in multivariate analyses. All calculations
were performed in Microsoft Excel (Microsoft Corpora-
tion, Redmond, WA) and Crystal Ball® software (Deci-
sioneering, Inc., Denver, CO).
Model overview and structure
We utilized the projected number of adult PAMV cases in
year 2020 [20] to allocate total bed days and costs in the
following annualized categories: MV days, non-MV ICU
days, total ICU days, non-ICU hospital days and total hos-
pital days. Additionally, based on previously reported
data [19], we projected the anticipated annualized vol-
ume of discharges to a SNF under an assumption that hos-
pital care delivery remains constant through year 2020.
Model inputs
Model input parameters and their sources are depicted in
Table 1.
Annual PAMV volume in referent year (2000) and projected to year 
2020
The source for this was a recent study based on the num-
bers from the Nationwide Inpatient Sample (NIS) [24,25]
focusing on adult discharges with the ICD-9-CM proce-
dure code 96.72 (MV for 96 hours or longer) [20]. This
study calculated both age-adjusted and condition-specific
changes in PAMV incidence and, projecting them out to
year 2020, reported that the number of PAMV discharges
from the US hospitals can be expected to rise from
252,577 in 2000 to 605,898 (95% confidence interval
[CI] 456,695 to 779,806) in 2020 [20].
Hospital services utilization parameters
While a previous study determined the median hospital
length of stay (LOS) in this population to be 17 days
(interquartile range [IQR] 25–75 11 to 26), correspond-
ing components of this utilization, i.e., duration of MV or
of ICU stay, were not quantified [19]. Since by virtue of
spending at least 96 hours on MV the PAMV patients fall
outside the estimated ranges for either acutely-ventilated
populations [26,27] or those on prolonged MV [28], we
developed the following approach to quantifying the MV
and ICU components of their hospital utilization:
1). We chose to focus on a population of patients who
require the longest time of MV during their acute ICU stay,
the groups with adult respiratory distress syndrome
(ARDS) [26]. The main rationale for this is that their
median time on MV is consistently estimated at > 96
hours [26,29]. Adding validity to this approach are the
similarities in both the median age and hospital mortality
among PAMV patients (35%) and those reported for the
ARDS population [19,29,30]. Finally, ARDS was a fre-
quently coded coexistent condition in the PAMV cohort
with the prevalence of 15% [19], though misclassification
was possible, given the administrative nature of the data
set.
2). Having made this choice, we developed estimates of
MV and ICU duration for this group based on a recent
robust and generalizable cohort study. The study by
Rubenfeld was a large prospective cohort study conducted
in King County, Washington, where 1,113 patients with
acute lung injury (ALI) and ARDS were enrolled [29]. In
this study, the median MV time was 5.3 days (IQR 25–75
2.1–10.8) and median ICU LOS 7.8 days (IQR 25–75 3.7–BMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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14.3). From these durations of individual components of
hospital stay we were able to derive the following param-
eter estimates: a). Duration of MV (5.3 days as reported by
Rubenfeld [29]), or 37.9% of the overall hospital LOS; b).
ICU LOS (7.8 days as reported by Rubenfeld [29]); c).
Duration of ICU without MV (total ICU LOS – MV dura-
tion), or 17.9% of the overall hospital LOS; and d). Non-
ICU hospital LOS (median hospital LOS for the PAMV
cohort [19] – ICU LOS reported by Rubenfeld [29]), or
44.3% of the overall hospital LOS.
3). In the final step, based on our previous report quanti-
fying the median hospital LOS in the PAMV population to
be 17 days [19], we computed the number of days spent
in each stratum of care by applying the proportions of
time spent in each of the strata by the ALI patients as
reported in the Rubenfeld study [29]. Each of the dura-
tions was rounded to the nearest integer.
Hospitalization component cost estimates
For the cost of MV we utilized the study by Dasta and col-
leagues, which quantified average daily costs for a patient
on MV through day 14 of MV. In this study using data
from 2002 the investigators demonstrated that day 1 of
MV is substantially more costly than all subsequent days.
To arrive at the point estimate of a daily cost for MV we
calculated a weighted average cost for a general ICU
patient (found under the rubric of "Total, $" in Table 4
[31]) in the Dasta paper ($3,948) and utilized extreme
values ($3,431 to $7,728) around that for the sensitivity
range, all inflated to 2008 $US as described below [31].
For both the non-MV ICU day and non-ICU hospital day
costs we went to a recent report from Halpern and col-
leagues, who, based on two distinct sources, calculated a
plausible range of these costs in year 2000 [12]. We aver-
aged each range to arrive at the point estimates for the
Table 1: Model Parameter Estimates and Sources
Input variable Point estimate Range (95% CI) Source/Calculation
VOLUME AND BED DAYS
Annual adult PAMV volume (number of discharges)
2000 252,577 N/A [25]
2020 605,898 456,695 to 779,806 [20]
Incremental LOS by level of service (days)
MV 6 4 to 11 [29]
Non-MV ICU 3 2 to 4 Total ICU – MV [29]
Total ICU 9 6 to 15 [29]
Non-ICU hospital 8 5 to 11 Median hospital LOS [19] – ICU LOS [29]
Total hospital 17 11 to 26 [19]
COSTS (2008 $US)
Cost of MV day $5,811 $5,050 to $11,374 [31]*
Cost of non-MV ICU day $2,880 $1,219 to $4,541 [12]†
Cost of non-ICU hospital day $1,170 $827 to $1,513 [12]†
PAMV is prolonged acute mechanical ventilation. LOS is length of stay. MV is mechanical ventilation. ICU is intensive care unit. CI is confidence 
interval. N/A is not applicable.
*Calculated as a weighted average cost based on reference 31 and utilized extreme values for the sensitivity range inflated to year 2008 $US.
†Based on reference 12, calculated as the average of the values computed by each reported method to arrive at the point estimates for the model, 
and varied the inputs across the corresponding ranges; inflated to year 2008 $US.BMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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model ($1,696 for non-MV ICU day and $689 for non-
ICU hospital day) and varied the inputs across the corre-
sponding ranges ($718 to $2,674 for non-MV ICU day
and $487 to $891 for non-ICU hospital day) [12].
Because variable costs are more likely than the fixed to be
impacted by population growth, and because variable
costs represent only 14% of total hospital costs [32], we
performed a sensitivity analysis to arrive at the potential
growth in this cost component specifically. Since it
remains unclear how much the projected PAMV growth
will impact the need to expand hospital plants, equip-
ment and personnel, this analysis represents the absolute
minimum of the incremental hospital expenditure that
may be expected in conjunction with this growth.
All costs were inflated to year 2008 $US using the hospital
and related services component of the Consumer Price
Index (CPI) [33]. To inflation-adjust our 2020 cost esti-
mates we calculated the most recent 10-year historic aver-
age annual inflation rate within the hospital and related
services component of CPI (8.5%) and applied that his-
toric growth to our projected number. We varied this
annual inflation rate between 6% and 12% in the simula-
tions. No discounting was required since the expenditures
we are quantifying are to take place in the future.
Volume of discharges to SNF estimate
This was based on the previous finding that 36% of all
PAMV patients are discharged from the hospital to a SNF
[19]. This proportion was multiplied by the projected
number of PAMV cases in 2020 to arrive at the base case,
and the bounds of the 95% CI of this estimate to generate
the corresponding 95% CI.
Monte Carlo Simulations
Because of uncertainties surrounding some of the param-
eter estimates in the model, we performed Monte Carlo
simulations to test the precision of our estimates. We var-
ied our inputs across their corresponding 95% CIs to gen-
erate the 95% CIs around the outcome estimates. Each
outcome estimate was tested in 10,000 trials. The proba-
bility distributions used for the input parameters were tri-
angular for the annual PAMV volume and log-normal for
the LOS estimates in each of the strata; in the case of the
latter log-normal was used as the best fit for non-paramet-
ric data. For cost inputs, we utilized a log-normal distribu-
tion for the cost of MV day, since this was based on the
non-parametrically distributed range, where early days are
more costly that those later on in the hospitalization [31].
The remaining cost estimates, as well as the annual infla-
tion rate, were varied across the normally distributed
ranges. Point estimates were calculated as the mean value
of the 10,000 trials and the 95% CIs represent 2.5th and
97.5th percentiles of the distributions.
Results
Over 50% of the duration of hospitalization among criti-
cally ill patients with respiratory failure is spent in the ICU
(Table 1). In this care stratum, the majority of the time is
allocated to MV support (37.9% of the total hospitaliza-
tion or 68% of the entire ICU time). In the setting of these
time allocations, the year 2000 estimate for correspond-
ing bed use is approximately 1.5 million MV days,
750,000 non-MV ICU days, and over 2 million non-ICU
hospital days. Given the projected increase of the PAMV
population to approximately 490,000 in year 2010 and to
over 600,000 cases in year 2020 [20], the corresponding
expected absolute increases in the care stratum-specific
bed days are an additional 1.3 and 2.1 million MV days,
2.0 and 3.2 million ICU days and 3.7 and 6.0 million total
hospital days in 2010 and 2020, respectively (Figure 1).
Put another way, we anticipate the bed demands to
increase from 1.5 to 3.6 million for MV, from 2.3 to 5.5
million for ICU, and from 4.3 to 10.3 million for annual-
ized hospital days between the years 2000 and 2020 in the
population requiring PAMV (Table 2). Additionally, dis-
charges to SNF can be expected to rise from 91,000 in year
2000 to nearly 220,000 by year 2020 (Table 2).
The results of the Monte Carlo simulations are also
depicted in Table 2, showing 95% confidence intervals
around the point estimates for each stratum of care. Thus,
the total volume of ICU days can be expected to range
from 4.2 to 7.0 million days in year 2020, and the total
hospital days between 8.1 and 13.0 million.
In terms of costs, PAMV population can be expected to
consume a total of $42.7 (95% CI $30.2 to $64.9) billion,
$10.6 (95% CI $7.3 to $16.2) billion, and $11.5 (95% CI
$8.0 to $17.3) billion in MV, non-MV ICU and non-ICU
hospital costs, respectively (Table 2). In other words, the
total projected costs of ICU care are $53.2 (95% CI $39.0
to $78.7) billion and the total costs of hospital care for the
PAMV population are $64.7 (95% CI $48.6 to $93.7) bil-
lion in year 2020. In a sensitivity analysis quantifying var-
iable costs only, the hospital costs consumed by PAMV
were $6.0 (95% CI $4.2 to $9.1), $1.5 (95% CI $1.0 to
$2.3), and $1.6 (95% CI $1.1 to $2.4) billion in MV, non-
MV ICU and non-ICU hospital costs, respectively, yielding
the total annual hospital bill of $9.1 (95% CI $6.8 to
$13.1) billion.
Importantly, an analysis of factors contributing to the
uncertainty in the model estimates quantifying bed occu-
pancy revealed that the imprecision of the projected
number of PAMV cases in year 2020 was responsible for
nearly all of the uncertainty, while the estimates of the
LOS did not make a significant contribution in the model
quantifying bed usage (Figure 2). In the model quantify-
ing costs, on the other hand, while the imprecision of theBMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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projected number of PAMV cases in year 2020 was respon-
sible for the majority of the outcome estimate uncertainty,
other factors also contributed substantial proportions of
the imprecision (Figure 3).
Discussion
We have shown that, based on previous projections for
their growth over time in the US, the PAMV population
can be expected to more than double their acute hospital
bed use in each of the care strata, as well as the use of SNF
as a discharge destination, resulting in 3.6 million MV, 5.5
million ICU and 10.3 million total hospital days in year
2020. While in the most modest growth scenario, this
change will be just under 2-fold, under the scenario of
greatest anticipated growth, the 2020 numbers may be as
high as 4.8 million, 7.0 million, and 13.0 million bed
days for MV, ICU and hospital, respectively. Similarly, the
corresponding inflation-adjusted costs can be expected to
be over $42, $53, and $64 billion for MV, ICU and total
hospital costs, respectively. Additionally, we project that,
in the absence of changes in care flow of the PAMV
patients, the volume of SNF discharges in this population
can be expected to be between roughly 177,000 and
267,000.
The landscape of hospital-based care in the US has under-
gone profound changes over the last 25 years. Following a
period of exuberant growth peaking in the 1970s at
~7,200 hospitals [34], the subsequent decades have seen
a steep reduction in inpatient utilization, and a decrease
in the number of hospitals to just under 5,500 [12]. This
decline has continued in the face of attempts to rein in
unprecedented healthcare expenditures, where hospital
care accounts for ~1/3 of the spending [14]. Indeed, in
Projected Annual Hospitalization Days in 10-year Increments Spent by a Patient on Prolonged Acute Mechanical Ventilation  (PAMV) in Various Strata of Hospital Care Figure 1
Projected Annual Hospitalization Days in 10-year Increments Spent by a Patient on Prolonged Acute Mechan-
ical Ventilation (PAMV) in Various Strata of Hospital Care. ICU is intensive care unit. MV is mechanical ventilation. Y 
is year.
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Table 2: Outcomes* †
Outcome Point Estimate 95% confidence interval*
Annual MV
2000 days 1,515,462 1,231,585 to 1,829,041
2020 days 3,635,388 2,735,290 to 4,838,746
2020 costs $42.7 $30.2 to $64.9
Annual non-MV ICU
2000 days 757,731 618,896 to 913,025
2020 days 1,897,694 1,373,865 to 2,437,155
2020 costs $10.6 $7.3 to $16.2
Total annualized ICU
2000 days 2,273,293 1,957,030 to 2,616,069
2020 days 5,453,082 4,246,669 to 7,020,137
2020 costs $53.2 $39.0 to $78.7
Annual non-ICU hospital
2000 days 2,020,616 1,658,582 to 2,445,627
2020 days 4,847,184 3,648,522 to 6,444,697
2020 costs $11.5 $8.0 to $17.3
Total annualized hospital
2000 days 4,293,809 3,811,826 to 5,323,280
2020 days 10,300,266 8,089,043 to 13,042,347
2020 costs $64.7 $48.6 to $93.7
Total annualized discharges to SNF
2000 90,928 N/A
2020 218,123 177,268 to 266,739
*Costs are in billions of $US; 95% confidence intervals estimated utilizing Monte Carlo simulations.
†Annual inflation rate of 8.5% calculated by averaging the 10-year historical inflation rate in the hospital and related care component between 1998 
and 2008 [33].
MV is mechanical ventilation. ICU is intensive care unit. SNF is skilled nursing facility.
N/A is not applicable.BMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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2005 there were just over 800,000 beds in community
hospitals across the US, or 2.71 beds per 1,000 popula-
tion, the lowest it has been in over two decades [16]. This
decrease is paradoxic, given that in-patient admissions
have been steadily on the rise since the mid-1990s, and
the average hospital LOS has not decreased appreciably
since year 2000 [16,25]. In contrast, the number of ICU
beds has increased by 26.2% from 69,300 to 87,400
between 1985 and 2000 [12], an approximate annual rate
of growth of 1.7%. If constant through year 2020, this will
result in a cumulative growth of 34% from the 2000 bed
number. It is unlikely that this modest rise in the number
of beds will be able to accommodate a nearly 140%
growth in bed demand by the PAMV population, since
already today among the hospitals reporting ED diver-
sion, the number one reason for this is the lack of staffed
ICU beds [16]. Commensurate with this growth in bed
utilization, as well as in view of expected inflation rates,
the annual spending on hospital care alone in this popu-
lation may be expected to rise from $16 billion in 2003 to
over $64 billion by 2020.
How can we address this projected rise in demand in ICU
and hospital services attributed to the growth in PAMV
population? In addition to making appropriate alloca-
tion, construction and staffing decisions, we need to focus
on optimizing the efficiency of care delivered to this and
other growing populations [35,36]. Starting upstream,
perhaps one lesson is to increase our attention to preven-
tion of complications that render one susceptible to a pro-
Tornado diagram. The solid vertical line represents the point estimate for the projected annualized hospital days occupied by  PAMV patients in year 2020. The horizontal bars represent the range of this difference when the corresponding single input is  varied across its designated range with all other input parameters held constant Figure 2
Tornado diagram. The solid vertical line represents the point estimate for the projected annualized hospital 
days occupied by PAMV patients in year 2020. The horizontal bars represent the range of this difference when 
the corresponding single input is varied across its designated range with all other input parameters held con-
stant. PAMV is prolonged acute mechanical ventilation. MV is mechanical ventilation. ICU is intensive care unit.
Total annualized hospital days 2020
10,000,000 15,000,000 20,000,000 25,000,000
Annual PAMV
volume 2020
Median MV days
Median nonMV ICU
days
Median nonICU hosp
daysBMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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longed critical illness. Our model suggests that this would
be most impactful, given that it is the number of PAMV
patients, and not the utilization at the individual level,
that is the strongest driver of the cumulative bed occu-
pancy. Short of this, and once critical illness has occurred,
adoption of such practices as lung-protective ventilation
[37], ventilator-associated pneumonia prevention [38],
sterile technique for central catheter insertion [39], and
limiting exposure to such potentially complicating agents
as allogeneic blood components [40-43] needs to be
locally optimized. Alternatively, in appropriate cases, a
stronger emphasis may be placed on end-of-life discus-
sions, resulting in elimination of care deemed unneces-
sary. Regionalization of care is worth considering.
However, while data suggest improved volume-outcomes
relationship in hospital survival for patients on MV, no
such link has been established for utilization outcomes
[27]. Finally, since a substantial body of information pro-
vides evidence that early tracheostomy may increase
patient comfort, has limited potential for harm and is at
the same time associated with a reduced time on MV and
in the ICU [44], it may be a viable strategy in at-risk
patients. However, should an early tracheostomy become
the standard of care, there will almost certainly be an
increased need in SNF facilities. In general, in view of
major improvements in outcomes among very low birth
weight infants, and the attendant increase in hospital
resource utilization, some lessons in how to manage
PAMV population growth may be derived from the expe-
riences of neonatal ICUs across the US [45].
Tornado diagram. The solid vertical line represents the point estimate for the projected annualized hospital costs for PAMV  patients in year 2020. The horizontal bars represent the range of this difference when the corresponding single input is varied  across its designated range with all other input parameters held constant Figure 3
Tornado diagram. The solid vertical line represents the point estimate for the projected annualized hospital 
costs for PAMV patients in year 2020. The horizontal bars represent the range of this difference when the cor-
responding single input is varied across its designated range with all other input parameters held constant. 
PAMV is prolonged acute mechanical ventilation. MV is mechanical ventilation. ICU is intensive care unit.
Total inflation-adjusted hospital stay dollars 2020
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MV days
Cost of MV day (2008 $US)
Annual inflation rate for hospital
and related services
Non-ICU hospital days
Cost of non-ICU hospital day
(2008 $US)
Non-MV ICU days
Cost of non-MV ICU day (2008
$US)BMC Health Services Research 2008, 8:242 http://www.biomedcentral.com/1472-6963/8/242
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Our study has multiple limitations. Although the proce-
dure code 96.72 has been used previously to identify the
PAMV population [19,20], neither its validity nor accu-
racy has been formally evaluated. The numbers we cite are
based on model simulations, and as such are sensitive to
the accuracy of input parameters. To incorporate the
uncertainty of input values into our estimates, we per-
formed Monte Carlo simulations and sensitivity analyses,
providing 95% confidence bounds for all of the estimates.
The estimates for the LOS in every stratum of hospital care
are derived from a single study of patients with acute lung
injury, and thus may not be generalizable to all PAMV
patients. However, given the fact that 15% of all PAMV
patients have a diagnosis code for ARDS, that hospital
mortality in PAMV patients is similar to that seen in
ARDS, and that the hospital LOS associated with PAMV
has been found to be similar to that seen in ARDS [19,29],
our estimates are likely to be in the right range. Addition-
ally, because the studies from which these critical inputs
were derived reported the LOS components as median
rather than mean values, our estimates likely underesti-
mate the true LOS. Another factor that adds to the internal
validity of this assumption is that when the hospital costs
reported for PAMV population in 2003 [19] are aggre-
gated and inflated to 2020 $US to reflect the projected
population, the total hospital costs ($68.1 billion) are
quite similar to those seen in the model ($64.7 billion).
Additionally, we have found that the bed utilization
model is most sensitive to the accuracy of the predicted
PAMV numbers, and not to the LOS inputs. A limitation
of using total hospital costs is worth discussing as well.
Since it has been shown that only a small fraction of the
total hospital costs is due to the variable component of
costs [32], our numbers likely overestimate the actual
incremental increases in expenditures necessary to care for
the growing PAMV population in the future. However,
even if a conservative estimate of 14% of the total costs is
used [32], the total annualized hospital costs associated
with the care of the PAMV population will approximate
$10 billion in variable hospital costs by 2020. This is a
three-fold growth compared to the 2003 estimate for the
indirect hospital costs for the care of this population [19].
Because one of the outcomes examined was the volume of
SNF discharges, the vague nature of the SNF definition has
to be brought up. Since the NIS does not explicitly provide
the definition, we assumed that, in accordance with Medi-
care, a SNF is "a nursing facility with the staff and equip-
ment to give skilled nursing care and/or skilled
rehabilitation services and other related health services",
and SNF care is defined as "a level of care that requires the
daily involvement of skilled nursing or rehabilitation staff
and that, as a practical matter, can't be provided on an
outpatient basis" [46]. Thus, it is likely that our SNF des-
ignation includes long-term acute care facilities, though
we cannot definitively state so. Finally, one of the major
underlying assumptions of the study is that the patterns of
care will remain the same. This assumption is not unrea-
sonable, given that translating evidence into practice can
take decades [47]. Thus, monitoring the volume of PAMV
patients longitudinally and measures to improve effi-
ciency in their care delivery will assure the accuracy of pre-
dictions in the future.
At the same time, our study has a number of strengths. To
the best of our knowledge, it is the first study to project
hospital utilization and costs by a large and growing
resource-intensive population. Furthermore, we have
divided this utilization estimate into the various strata of
hospital care relevant to making decisions with regard to
budgeting, construction, equipment and hospital person-
nel allocations. For example, given that the number of MV
days may double if no measures, such as early tracheos-
tomy or regionalization of care, prove effective at reducing
this duration, a hospital may need to include such capital
investments as the purchase of additional ventilators in its
planning efforts.
In summary, we have demonstrated that hospital bed uti-
lization between years 2000 and 2020 will go from 1.5 to
3.6 million for MV, from 2.3 to 5.5 million ICU, and from
4.3 to 10.3 million annualized hospital days for the pop-
ulation requiring PAMV, and the expected annual hospital
costs may be over $64 billion. Our projections put into
perspective the fact that efficiency improvements can no
longer be viewed as an option, but are a clinical and policy
imperative.
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